Relenza zanamivir inhaled neuraminidase inhibitor regulatory update

BTA partner Glaxo Wellcome plc (London, U.K.) submitted an application for European marketing approval of Relenza to prevent influenza infection, and to treat and prevent influenza in pediatric patie...